Affinity DataIC50: 0.190nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.246nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.274nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.287nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.325nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.330nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.363nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.372nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.388nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.388nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.394nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.401nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.407nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.419nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.429nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
Affinity DataIC50: 0.430nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.432nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.448nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
Affinity DataIC50: 0.450nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.459nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.472nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.473nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.475nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFRβ (amino acids R561-L1106), expr...More data for this Ligand-Target Pair
Affinity DataIC50: 0.480nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.487nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFRβ (amino acids R561-L1106), expr...More data for this Ligand-Target Pair
Affinity DataIC50: 0.490nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
Affinity DataIC50: 0.490nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.496nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.498nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.503nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.503nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
Affinity DataIC50: 0.510nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
Affinity DataIC50: 0.520nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.522nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.525nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
Affinity DataIC50: 0.540nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.548nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
Affinity DataIC50: 0.560nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.573nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.578nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.580nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.582nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.595nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
Affinity DataIC50: 0.600nMAssay Description:Antagonist activity at adenosine A1 receptor by cAMP assayMore data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.601nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
Affinity DataIC50: 0.610nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.613nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.618nMpH: 7.0Assay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human KDR (amino acids D807-V1356), expresse...More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft
US Patent
Bayer Pharma Aktiengesellschaft
US Patent
Affinity DataIC50: 0.626nMpH: 7.5 T: 2°CAssay Description:The kinase used was a recombinant fusion protein composed of N-terminal GST and a C-terminal fragment of human PDGFRβ (amino acids R561-L1106), expr...More data for this Ligand-Target Pair
Affinity DataIC50: 0.630nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair